SiRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma

Journal of Molecular Recognition

Volumn 26, Issue 7, 2013, Pages 318-329

  Ramon, A L ^a,b,c   Bertrand, J R ^a   De Martimprey, H ^a,b   Bernard, G ^d   Ponchel, G ^b,c   Malvy, C ^a   Vauthier, C ^b,c  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIV PARIS SUD   (France)

^d INSERM   (France)

Author keywords

chitosan; Ewing's sarcoma; immunonanoparticles; poly(alkylcyanoacrylate) nanoparticles; siRNA

Indexed keywords

CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CHITOSAN; LEUKOCYTE ANTIGEN; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; EWING SARCOMA; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ANTIGENS, CD; CELL ADHESION MOLECULES; CHITOSAN; HUMANS; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; POLYMERS; RNA, SMALL INTERFERING; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877691655     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2276     Document Type: Article

References (33)

1. Alhaddad A, Adam MP, Botsoa J, Dantelle G, Perruchas S, Gacoin T, Mansuy C, Lavielle S, Malvy C, Treussart F, Bertrand JR,. 2011. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 7: 3087-3095. DOI: 10.1002/smll.201101193.
2. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M,. 1991. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67: 1886-1893. DOI: 10.1002/1097- 0142(19910401).
3. Bertholon I, Lesieur S, Labarre D, Besnard M, Vauthie C,. 2006a. Characterization of dextran-poly(isobutylcyanoacrylate) copolymers obtained by redox radical and anionic emulsion polymerization. Macromolecules 39: 3559-3567. DOI: 10.1021/ma060338z.
4. Bertholon I, Vauthier C, Labarre D,. 2006b. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm. Res. 23: 1313-1323. DOI: 10.1007/s11095-006-0069-0.
5. Bravo-Osuna I, Ponchel G, Vauthier C,. 2007. Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles. Eur. J. Pharm. Sci. 30: 143-154. DOI: 10.1016/j.ejps.2006.10.007.
6. Chauvierre C, Leclerc L, Labarre D, Appel M, Marden MC, Couvreur P, Vauthier C,. 2007. Enhancing the tolerance of poly(isobutylcyanoacrylate) nanoparticles with a modular surface design. Int. J. Pharm. 338: 327-332. DOI: 10.1016/j.ijpharm.2007.01.034.
7. Daka A, Peer D,. 2012. RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. DOI: 10.1016/j.addr.2012.08.014.
8. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Pete M, Kovar H, Jouber I, de Jon P, Rouleau G, Aurias A,., Thomas G,. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165. DOI: 10.1038/359162a0.
9. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E,. 2010. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr. Blood Cancer 54: 13-18. DOI: 10.1002/pbc.22245.
10. Elhamess H, Bertrand JR, Maccario J, Maksimenko A, Malvy C,. 2009. Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles. Oligonucleotides 19: 255-264. DOI: 10.1089/oli.2009.0197.
11. Esiashvili N, Goodman M, Marcus RB Jr., 2008. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J. Pediatr. Hematol. Oncol. 30: 425-430. DOI: 10.1097/MPH.0b013e31816e22f3.
12. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ,. 2005a. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 65: 4633-4644. DOI: 10.1158/0008-5472.CAN-04-2857.
13. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ,. 2005b. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65: 8984-8992. DOI: 10.1158/0008-5472.CAN-05-0565.
14. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS,. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21: 635-637. DOI: 10.1038/nbt831.
15. Lin RY, Dayananda K, Chen TJ, Chen CY, Liu GC, Lin KL, Wang YM,. 2012. Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging. Contrast Media Mol. Imaging 7: 7-18. DOI: 10.1002/cmmi.457.
16. Liu P, Wang H, Wang Q, Sun Y, Shen M, Zhu M, Wan Z, Duan Y,. 2012. cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted Delivery of fluorouracil. J. Nanosci. Nanotechnol. 12: 4467-4471. DOI: 10.1166/jnn.2012.6213.
17. Lv PP, Ma YF, Yu R, Yue H, Ni DZ, Wei W, Ma GH,. 2012. Targeted delivery of insoluble cargo (paclitaxel) by PEGylated chitosan nanoparticles grafted with Arg-Gly-Asp (RGD). Mol. Pharm. 9: 1736-1747. DOI: 10.1021/mp300051h.
18. de Martimprey H, Bertrand JR, Fusco A, Santoro M, Couvreur P, Vauthier C, Malvy C,. 2008. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36: e2. DOI: 10.1093/nar/gkm1094.
19. de Martimprey H, Bertrand JR, Malv C, Couvreur P, Vauthier C,. 2009. New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm. Res. 27: 498-509. DOI: 10.1007/s11095-009- 0043-8.
20. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT,. 1997. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat. Genet. 17: 495-497. DOI: 10.1038/ng1297-495.
21. Nobs L, Buchegger F, Gurny R, Allemann E,. 2006. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug. Chem. 17: 139-145. DOI: 10.1021/bc050137k.
22. Persengiev SP, Zhu X, Green MR,. 2004. Nonspecific, concentration- dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10: 12-18. DOI: 10.1261/rna5160904.
23. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE,. 2004. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 64: 1266-1277. DOI: 10.1158/0008-5472.CAN-03-3274.
24. Saxena V, Naguib Y, Hussain MD,. 2010. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloids Surf. B Biointerfaces 94: 274-280. DOI: 10.1016/j.colsurfb.2012.02.001.
25. Segura-Sanchez F, Montembault V, Fontaine L, Martinez-Barbosa ME, Bouchemal K, Ponchel G,. 2010. Synthesis and characterization of functionalized poly(gamma-benzyl-L-glutamate) derivates and corresponding nanoparticles preparation and characterization. Int. J. Pharm. 387: 244-252. DOI: 10.1016/j.ijpharm.2009.12.016.
26. Srinivasan C, Peer D, Shimaoka M,. 2012. Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivo. Methods Mol. Biol. 820: 105-116. DOI: 10.1007/978-1-61779-439-1-7.
27. Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, Kawai G, Saitou M, Matsuhashi A, Yamada K, Shimizu K,. 2011. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int. J. Cancer 128: 216-226. DOI: 10.1002/ijc.25564.
28. Toub N, Bertrand JR, Tamaddon A, Elhamess H, Hillaireau H, Maksimenko A, Maccario J, Malvy C, Fattal E, Couvreur P,. 2006. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 23: 892-900. DOI: 10.1007/s11095-006-9901-9.
29. Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM,. 1984. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet. Cytogenet. 12: 1-19. DOI: 10.1016/0165-4608(84)90002-5.
30. Vauthier C, Persson B, Lindner P, Cabane B,. 2011. Protein adsorption and complement activation for di-block copolymer nanoparticles. Biomaterials 32: 1646-1656. DOI: 10.1016/j.biomaterials.2010.10.026.
31. Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, Lu D, Liu Y, Fan Y, Zheng Y, Han Z, Kong D, Wu JC, Xiang R, Li Z,. 2012. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33: 5107-5114. DOI: 10.1016/j.biomaterials.2012.03.067.
32. Wright LD, Skeggs HR, Cresson EL,. 1947. Affinity of avidin for certain analogs of biotin. Proc. Soc. Exp. Biol. Med. 64: 150-153. DOI: 10.3181/00379727-64-15729.
33. Zandanel C, Vauthier C,. 2012. Characterization of fluorescent poly(isobutylcyanoacrylate) nanoparticles obtained by copolymerization of a fluorescent probe during redox radical emulsion polymerization (RREP). Eur. J. Pharm. Biopharm. 82: 66-75. DOI: 10.1016/j.ejpb.2012.05.002.